Saffrotin Capsule (Alzheimer’s Improver)
In laboratory studies, the presence of Crocin in Saffron, which is the main ingredient of this product, has been shown to prevent the growth of neuronal death and brain atrophy. Increasing the level and activity of redox in the brain is the goal of many studies in treating Alzheimer’s. The use of this product has […]
In laboratory studies, the presence of Crocin in Saffron, which is the main ingredient of this product, has been shown to prevent the growth of neuronal death and brain atrophy.
Increasing the level and activity of redox in the brain is the goal of many studies in treating Alzheimer’s. The use of this product has a very effective effect on increasing the activity of the redox activity in the brain.
Modifying effects of Saffron-based derivatives on glutamate and NMDA receptors have been proven in several studies and its effect is such as the Mamentin drug, however that these active ingredients have no side effects.
In a study, 54 patients with mild to moderate Alzheimer’s disease were divided into two groups and treated with Saffron capsules or Duplex capsules for 22 weeks. The stunning results of this clinical trial indicated that Saffron capsule has a similar effect to Dopedel capsules in improving symptoms.
In addition, adverse effects in patients treated with Dopedysil was much higher than that of Saffron capsule group.
Slows down or improves memory impairment due to Alzheimer’s disease
Dosage form and packaging
60 Capsules 15 mg
Saffron (Crocus sativus)
1 capsule after breakfast and 1 after dinner.
Response to saffron may take 6-8 weeks.
Alzheimer’s disease (AD) is the most common form of dementia in the elderly. This condition is characterized by a progressive loss of memory, deterioration of virtually all intellectual functions, increased apathy, decreased speech function, disorientation, and gait irregularities.
AD is the most widely known of degenerative diseases. It is a condition that is commonly associated with considerable psychological and emotional distress for patients and their families.
As of 2008, there is an estimation of 30 million people with dementia worldwide. By 2050, it is projected that this figure will have increased to over 100 million individuals! The results of two randomized clinical trials indicate that patients with mild-to-moderate AD receiving C. sativus extract experienced statistically significant benefits in cognition after 22 weeks of treatment.
In conditions like bleeding disorders, administration of saffron is contraindicated.
Research has not yet established conclusively whether or not saffron during pregnancy or lactation is safe. Hence, it should be avoided by women at the said stages.
* If you are taking other medications, consult your doctor before taking this product.
* Do not exceed the recommended dose.
* Store at room temperature (0-30ºC).
* Protect from direct light and heat.
* Keep out of the reach of children.